At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

For more information kindly visit our website www.marketresearchfuture.com or contact us at info@marketresearchfuture.com

Copyright © 2021 Market Research Future
All Rights Reserved. This document contains highly confidential information and is the sole property of Market Research Future. No part of it may be circulated, copied, quoted, or otherwise reproduced without the written approval of Market Research Future.
Endometrial Cancer Market Research Report - Forecast to 2027

Endometrial Cancer Market Scenario

The abnormal growth of endometrium cells in the uterus is termed as endometrial cancer which is also known as uterine cancer. Endometrial cancer is diagnosed at an early stage as women experience abnormal vaginal bleeding. It is reported that endometrial cancer is the sixth most common cancer in women all over the world. The endometrial cancer market is expected to witness a tremendous growth owing to the rising prevalence of endometrial cancer. Other key factors such as the growing obesity among women, increase in menopausal hormone therapy, change in sedentary lifestyle, socioeconomic factors, growing consumption of unhealthy diet, increasing incidence of Polycystic Ovarian Syndrome (PCOS), and increasing prevalence of breast or ovarian tumor are contributing towards the growth of the market. Diabetes is another risk factor that leads to the development of endometrial cancer. According to the American Cancer Society, endometrial cancer is four times common in diabetic women than in normal women. Such factors contribute to endometrial cancer among women.

However, factors such as high cost of diagnostic procedures, expensive treatments, and side effects associated with hysterectomy procedures are expected to restrict the market growth during the forecast period.

Research Methodology

Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.

- Primary Research

Extensive primary research was conducted to gain a deeper insight into the market and the industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of the major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.

- Secondary Research

Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the endometrial cancer market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company websites, international organization of chemical manufacturers, some paid databases, and many others.

Segmentation

The endometrial cancer market is segmented on the basis of diagnosis, treatment, and end-user. The endometrial cancer market, by diagnosis, is categorized into pelvic examination, transvaginal ultrasound, endometrial biopsy, dilation and curettage (D&C), and laparoscopy. On the basis of treatment, the market is segmented into hysterectomy techniques, radiation, hormone therapy, chemotherapy, and palliative care. The hysterectomy techniques category includes open abdominal hysterectomy, total vaginal hysterectomy, total laparoscopic hysterectomy, and robotic hysterectomy. The radiation category includes external radiation and internal radiation (brachytherapy). The hormonal therapy includes progestins, tamoxifen, luteinizing hormone-releasing hormone agonists, and aromatase inhibitors. The chemotherapy segment is categorized into paclitaxel, carboplatin, doxorubicin, and cisplatin. On the basis of end-user, the market is segmented into hospitals and clinics,
ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers, and others.

On the basis of region, the endometrial cancer market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Key players

Some of the key players in the market are Pfizer Inc., General Electric Company, Koninklijke Philips N.V., LUPIN, PHYTON, Bayer AG, Celgene Corporation, Johnson & Johnson, CooperSurgical Inc., LiNA Medical USA, Conceptus Inc., Hologic Inc., Karl Storz GmbH & Co. Kg, and Boston Scientific Corporation.

Regional Market Summary

The endometrial cancer market is dominated by North America owing to the rising prevalence of breast cancer. The US Breast Cancer Statistics projected 266,120 new cases of invasive breast cancer and 63,960 new cases of non-invasive breast cancer in 2018. Other factors such as increasing healthcare expenditure and increasing obesity within the female population drive the market growth in this region.

It is estimated that Europe stood second in the endometrial cancer industry owing to the increasing prevalence of ovarian cancer in this region. According to the Cancer Research UK in 2015, 7270 new cases of ovarian cancer were registered in the UK. Thus, the increasing prevalence of ovarian cancer in this region influences the growth of this market in this region.

Asia-Pacific was projected to be the fastest growing region for the endometrial cancer market in 2017. The market is expected to witness growth owing to the rising prevalence of diabetes in women, changing lifestyle, and growing obesity within the female population. According to the American Diabetes Association, diabetes in South Asia is expected to rise by 150% from 2000 to 2035. This provides a favorable background for the market to grow.

The Middle East and Africa holds the least share in the endometrial cancer market due to the presence of stringent government policies and poor economies. However, the market is expected to witness growth due to the rising healthcare expenditure, growing private sector in the healthcare domain, and insurance coverage in the Middle East.

Endometrial Cancer Market Share (%), by Region, 2017
Endometrial Cancer Market, by Treatment

- **Hysterectomy Techniques**
  - Open abdominal hysterectomy
  - Total vaginal hysterectomy
  - Total laparoscopic hysterectomy
  - Robotic hysterectomy

- **Radiation**
  - External radiation
  - Internal radiation (brachytherapy)

- **Hormone therapy**
  - Progestins
  - Tamoxifen
  - Luteinizing hormone-releasing hormone agonists
  - Aromatase inhibitors

- **Chemotherapy**
  - Paclitaxel
  - Carboplatin
  - Doxorubicin
  - Cisplatin

- **Palliative care**

Endometrial Cancer market, by End-User

- Hospitals & Clinics
- Ambulatory Surgical Centers
- Diagnostic Centers
- Gynecology Centers
- Feminist Health Centers

Endometrial Cancer Market, by Region

- The Americas
- Europe
- Asia-Pacific
- The Middle East & Africa

Endometrial Cancer Market, by Key Players

- Pfizer Inc.
- General Electric Company
- Koninklijke Philips N.V.
• LUPIN, PHYTON
• Bayer AG
• Celgene Corporation
• Johnson & Johnson
• CooperSurgical Inc.
• LINA Medical USA
• Conceptus Inc.
• Hologic Inc.
• Karl Storz GmbH & Co. Kg.
• Boston Scientific Corporation

Intended Audience

• Pharmaceutical companies
• Biotechnological institutes
• Government and private laboratories
• Research and Development (R&D) companies
• Medical research laboratories
• Market research and consulting service providers
GLOBAL ENDOMETRIAL CANCER MARKET

Endometrial Cancer market is expected to witness tremendous growth with lucrative CAGR over the forecast period.

**BY DIAGNOSIS**
- Pelvic examination
- Transvaginal ultrasound
- Endometrial biopsy
- Dilation and curetage (D&C)
- Diagnostic laparoscopy

**BY TREATMENT**
- Hysterectomy Techniques
- Radiation
- Hormone therapy
- Chemotherapy
- Palliative care

**BY END USER**
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Diagnostic Centers
- Gynecology Centers
- Feminist Health Centers

**BY REGION**
- North America
- Europe
- Asia-Pacific
- Rest of the World

---

**DRIVERS:**
- Rising prevalence of endometrial cancer and increasing occurrence of Polycystic Ovarian Syndrome (PCOS)
- Growing obesity among women, change in sedentary lifestyle and rising consumption of unhealthy diet

**RESTRRAINT:**
- High cost of advanced medical carts in developing countries may hamper the market growth

**KEY PLAYERS:**
- Pfizer Inc.
- General Electric Company
- Koninklijke Philips N.V.
- LUPIN, FYTON
- Bayer AG
- Celgene Corporation
- Johnson & Johnson
- CooperSurgical Inc.
- LIMA Medical USA
- Conceptus Inc.
- Hologic Inc.
Table of Content:

TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
  2.1 Definition
  2.2 Scope of the Study
  2.2.1 Research Objective
  2.2.2 Assumptions
  2.2.3 Limitations
Chapter 3. Research Methodology
  3.1 Introduction
  3.2 Primary Research
  3.3 Secondary Research
  3.4 Market Size Estimation
Chapter 4. Market Dynamics
  4.1 Drivers
  4.2 Restraints
  4.3 Opportunities
  4.4 Challenges
  4.5 Macroeconomic Indicators
  4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
  5.1 Porter’s Five Forces Analysis
    5.1.1 Bargaining Power of Suppliers
    5.1.2 Bargaining Power of Buyers
    5.1.3 Threat of New Entrants
    5.1.4 Threat of Substitutes
    5.1.5 Intensity of Rivalry
  5.2 Value Chain Analysis
  5.3 Investment Feasibility Analysis
  5.4 Pricing Analysis
Chapter 6. Global Endometrial Cancer Market, by Diagnosis
  6.1 Introduction
    6.2 Pelvic examination
    6.3 Transvaginal ultrasound
    6.4 Endometrial biopsy
    6.5 Dilation and curettage (D&C)
    6.6 Diagnostic laparoscopy
Chapter 7. Global Endometrial Cancer Market, by Treatment
  7.1 Introduction
    7.2 Hysterectomy Techniques
      7.2.1 Open abdominal hysterectomy
      7.2.2 Total vaginal hysterectomy
      7.2.3 Total laparoscopic hysterectomy
      7.2.4 Robotic hysterectomy
    7.3 Radiation
      7.3.1 External radiation
      7.3.2 Internal radiation (brachytherapy)
    7.4 Hormone therapy
      7.4.1 Progestins
      7.4.2 Tamoxifen
      7.4.3 Luteinizing hormone-releasing hormone agonists
      7.4.4 Aromatase inhibitors
    7.5 Chemotherapy
      7.5.1 Paclitaxel
      7.5.2 Carboplatin
      7.5.3 Doxorubicin
      7.5.4 Cisplatin
    7.6 Palliative care
Chapter 8. Global Endometrial Cancer market, by End-User
  8.1 Introduction
  8.2 Hospitals & Clinics
  8.3 Ambulatory Surgical Centers
  8.4 Diagnostic Centers
  8.5 Gynecology Centers
  8.6 Feminist health centers
Chapter 9. Global Endometrial Cancer Market, by Region
  9.1 Introduction
  9.2 America
    9.2.1 North America
      9.2.1.1 US
    9.2.2 South America
    9.3 Europe
      9.3.1 Western Europe
        9.3.1.1 Germany
      9.3.2 France
      9.3.3 Italy
      9.3.4 Spain
      9.3.5 UK
      9.3.6 Rest of Western Europe
    9.3.2 Eastern Europe
    9.4 Asia-Pacific
    9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia-Pacific
9.5 The Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Pfizer Inc
11.1.1 Company Overview
11.1.2 Type Overview
11.1.3 Financials
11.2.4 Key Developments
11.1.5 SWOT Analysis
11.2 Koninklijke Philips N.V
11.2.1 Company Overview
11.2.2 Type Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Boston Scientific Corporation
11.3.1 Company Overview
11.3.2 Type Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 LUPIN
11.4.1 Company Overview
11.4.2 Type/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 PHYTON
11.5.1 Company Overview
11.5.2 Type Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 Bayer AG
11.6.1 Company Overview
11.6.2 Type Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 CELGENE CORPORATION
11.7.1 Overview
11.7.2 Type Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 Johnson & Johnson
11.8.1 Overview
11.8.2 Type Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 CooperSurgical Inc.
11.9.1 Overview
11.9.2 Type Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 LIN Medical USA
11.10.1 Overview
11.10.2 Type Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 CONCEPTUS INC
11.11.1 Overview
11.11.2 Type Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.12 Hologic Inc.
11.12.1 Overview
11.12.2 Type Overview